Could a common diabetes drug shield heart transplant patients from kidney damage?
NCT ID NCT06625073
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether empagliflozin (Jardiance), a drug used for diabetes, can protect the kidneys and heart in people who have had a heart transplant. About 200 veterans will take either the drug or a placebo daily for 12 months. The goal is to see if it improves kidney function and reduces heart and metabolic risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunter Holmes McGuire VA Medical Center, Richmond, VA
NOT_YET_RECRUITINGRichmond, Virginia, 23249-0001, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Michael E. DeBakey VA Medical Center, Houston, TX
NOT_YET_RECRUITINGHouston, Texas, 77030-4211, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
NOT_YET_RECRUITINGNashville, Tennessee, 37212-2637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Palo Alto Health Care System, Palo Alto, CA
NOT_YET_RECRUITINGPalo Alto, California, 94304-1207, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Salt Lake City Health Care System, Salt Lake City, UT
RECRUITINGSalt Lake City, Utah, 84148-0001, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
William S. Middleton Memorial Veterans Hospital, Madison, WI
NOT_YET_RECRUITINGMadison, Wisconsin, 53705-2254, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance)
What this could lead to
If it works, this could provide a new way to protect kidney and heart health in heart transplant recipients, reducing complications.
What could go wrong
This is a relatively small, early-phase trial in a specific population (veterans). The drug may not show clear benefits or could cause side effects like infections or dehydration.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.